We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Abbott Molecular’s Des Plaines, Ill., facility has received a Form 483 noting its corrective and preventive action procedure does not provide sufficient detail for conducting searches of exceptions, such as noncompliances, to determine the severity of the impact to product quality.